Fig. 6
RNA interference against Wnt1 rescues cDCs from b-catenin activation and synergizes with DC-targeted therapies. a In vitro proliferation of Wnt1 overexpressing LLC cells in the presence of siWnt1 RNA nanoliposomes. MTT assay (left) and Ki67 expression (right). b Confocal photos showing lung tumor localization of intraperitoneal administered Cy3 loaded DOPC nanoliposomes. c siWnt1 or siControl RNA nanoparticles were administered to mice bearing Wnt1 overexpressing OVA-LLC lung tumors in vivo. FACS contour plots of Wnt1 expression by mCherry+ LLC and mCherry− tumor stroma cells (Left). Cumulative data (right). d Representative FACS contour plots depict active b-catenin expression by cDCs (left). Cumulative data (right). e In vivo lung tumor growth. siWnt1 was given therapeutically either as single agent or in combination with a-DEC205-OVA plus polyI/C (left) or Flt3Ligand (right). f Immunotherapeutic efficacy of siWnt1-loaded nanoparticles in autochthonous urethane-induced lung adenocarcinomas. siWnt1 or siControl RNA nanoparticles were administered to mice bearing established urethane-induced lung tumors in vivo (left up). Representative FACS histogram plots of Wnt1 expression by CD45−CD31−FAP− cells (left bottom). Cumulative data showing tumor burden, numbers of lung T cytotoxic cells and b-catenin active cDCs (right). c–f Data are representative or cumulative of at least two independent experiments with 4–9 mice per group. Error bars represent mean with SEM. *p < 0.05; **p < 0.01, Mann–Whitney. Source data are provided as a Source Data file
